209 related articles for article (PubMed ID: 31482509)
1. Adherence, Persistence, and Switching Among People Prescribed Sodium Glucose Co-transporter 2 Inhibitors: A Nationwide Retrospective Cohort Study.
Ofori-Asenso R; Liew D; Lalic S; Mazidi M; Magliano DJ; Ademi Z; Bell JS; Ilomaki J
Adv Ther; 2019 Nov; 36(11):3265-3278. PubMed ID: 31482509
[TBL] [Abstract][Full Text] [Related]
2. Dynamics of switching, adherence, and persistence of dipeptidyl peptidase-4 inhibitors use: A nationwide cohort study.
Ofori-Asenso R; Ilomaki J; Chin KL; Mazidi M; Zomer E; Bell JS; Magliano DJ; Liew D
Diabetes Res Clin Pract; 2019 Dec; 158():107909. PubMed ID: 31697992
[TBL] [Abstract][Full Text] [Related]
3. Adherence and persistence in patients with type 2 diabetes mellitus newly initiating canagliflozin, dapagliflozin, dpp-4s, or glp-1s in the United States.
Cai J; Divino V; Burudpakdee C
Curr Med Res Opin; 2017 Jul; 33(7):1317-1328. PubMed ID: 28418262
[TBL] [Abstract][Full Text] [Related]
4. Poor adherence and persistence to sodium glucose co-transporter 2 inhibitors in real-world settings: Evidence from a systematic review and meta-analysis.
Ofori-Asenso R; Sahle BW; Chin KL; Mazidi M; Ademi Z; De Bruin ML; Liew D
Diabetes Metab Res Rev; 2021 Jan; 37(1):e3350. PubMed ID: 32447808
[TBL] [Abstract][Full Text] [Related]
5. Retrospective analysis of long-term adherence to and persistence with DPP-4 inhibitors in US adults with type 2 diabetes mellitus.
Farr AM; Sheehan JJ; Curkendall SM; Smith DM; Johnston SS; Kalsekar I
Adv Ther; 2014 Dec; 31(12):1287-305. PubMed ID: 25504156
[TBL] [Abstract][Full Text] [Related]
6. Real-world adherence, persistence, and in-class switching during use of dipeptidyl peptidase-4 inhibitors: a systematic review and meta-analysis involving 594,138 patients with type 2 diabetes.
Ogundipe O; Mazidi M; Chin KL; Gor D; McGovern A; Sahle BW; Jermendy G; Korhonen MJ; Appiah B; Ademi Z; De Bruin ML; Liew D; Ofori-Asenso R
Acta Diabetol; 2021 Jan; 58(1):39-46. PubMed ID: 32809070
[TBL] [Abstract][Full Text] [Related]
7. Switching, Persistence and Adherence to Statin Therapy: a Retrospective Cohort Study Using the Australian National Pharmacy Data.
Talic S; Marquina C; Ofori-Asenso R; Petrova M; Liew D; Owen AJ; Lybrand S; Thomson D; Ilomaki J; Zomer E; Ademi Z
Cardiovasc Drugs Ther; 2022 Oct; 36(5):867-877. PubMed ID: 34097194
[TBL] [Abstract][Full Text] [Related]
8. Impact of medication adherence and persistence on clinical and economic outcomes in patients with type 2 diabetes treated with liraglutide: a retrospective cohort study.
Buysman EK; Liu F; Hammer M; Langer J
Adv Ther; 2015 Apr; 32(4):341-55. PubMed ID: 25832470
[TBL] [Abstract][Full Text] [Related]
9. Adherence and Persistence with DPP-4 Inhibitors Versus Pioglitazone in Type 2 Diabetes Patients with Chronic Kidney Disease: A Retrospective Claims Database Analysis.
Gor D; Lee TA; Schumock GT; Walton SM; Gerber BS; Nutescu EA; Touchette DR
J Manag Care Spec Pharm; 2020 Jan; 26(1):67-75. PubMed ID: 31880221
[TBL] [Abstract][Full Text] [Related]
10. Association of Prescription Co-payment With Adherence to Glucagon-Like Peptide-1 Receptor Agonist and Sodium-Glucose Cotransporter-2 Inhibitor Therapies in Patients With Heart Failure and Diabetes.
Essien UR; Singh B; Swabe G; Johnson AE; Eberly LA; Wadhera RK; Breathett K; Vaduganathan M; Magnani JW
JAMA Netw Open; 2023 Jun; 6(6):e2316290. PubMed ID: 37261826
[TBL] [Abstract][Full Text] [Related]
11. Comparative persistence and adherence with newer anti-hyperglycemic agents to treat patients with type 2 diabetes in the United States.
Cai J; Wang Y; Baser O; Xie L; Chow W
J Med Econ; 2016 Dec; 19(12):1175-1186. PubMed ID: 27356271
[TBL] [Abstract][Full Text] [Related]
12. Comparative cardiovascular outcomes in type 2 diabetes patients taking dapagliflozin versus empagliflozin: a nationwide population-based cohort study.
Lim J; Choi YJ; Kim BS; Rhee TM; Lee HJ; Han KD; Park JB; Na JO; Kim YJ; Lee H; Kim HK
Cardiovasc Diabetol; 2023 Jul; 22(1):188. PubMed ID: 37496050
[TBL] [Abstract][Full Text] [Related]
13. Characteristics Relating to Adherence and Persistence to Basal Insulin Regimens Among Elderly Insulin-Naïve Patients with Type 2 Diabetes: Pre-Filled Pens versus Vials/Syringes.
Slabaugh SL; Bouchard JR; Li Y; Baltz JC; Meah YA; Moretz DC
Adv Ther; 2015 Dec; 32(12):1206-21. PubMed ID: 26563324
[TBL] [Abstract][Full Text] [Related]
14. A 5-year trend in the use of sodium-glucose co-transporter 2 inhibitors and other oral antidiabetic drugs in a Middle Eastern country.
Zaghloul N; Awaisu A; Mahfouz A; Alyafei S; Elewa H
Int J Clin Pharm; 2022 Dec; 44(6):1342-1350. PubMed ID: 36169802
[TBL] [Abstract][Full Text] [Related]
15. Three Sides to the Story: Adherence Trajectories During the First Year of SGLT2 Inhibitor Therapy Among Medicare Beneficiaries.
Hawley CE; Lauffenburger JC; Paik JM; Wexler DJ; Kim SC; Patorno E
Diabetes Care; 2022 Mar; 45(3):604-613. PubMed ID: 35043165
[TBL] [Abstract][Full Text] [Related]
16. Adherence to statin treatment and health outcomes in an Italian cohort of newly treated patients: results from an administrative database analysis.
Degli Esposti L; Saragoni S; Batacchi P; Benemei S; Geppetti P; Sturani A; Buda S; Degli Esposti E
Clin Ther; 2012 Jan; 34(1):190-9. PubMed ID: 22284998
[TBL] [Abstract][Full Text] [Related]
17. Incidence and Predictors of Primary Nonadherence to Sodium Glucose Co-transporter 2 Inhibitors and Glucagon-Like Peptide 1 Agonists in a Large Integrated Healthcare System.
Luo J; Feldman R; Rothenberger S; Korytkowski M; Fischer MA; Gellad WF
J Gen Intern Med; 2022 Nov; 37(14):3562-3569. PubMed ID: 35048301
[TBL] [Abstract][Full Text] [Related]
18. Study comparing the efficacy and renal safety for patients with diabetes switching from dapagliflozin to empagliflozin.
Yang AY; Chen HC
Int J Clin Pharm; 2021 Aug; 43(4):1015-1023. PubMed ID: 33258006
[TBL] [Abstract][Full Text] [Related]
19. Disparities in Initial Oral Antidiabetic Medication Adherence Among Veterans with Incident Diabetes.
Gatwood JD; Chisholm-Burns M; Davis R; Thomas F; Potukuchi P; Hung A; Kovesdy CP
J Manag Care Spec Pharm; 2018 Apr; 24(4):379-389. PubMed ID: 29578849
[TBL] [Abstract][Full Text] [Related]
20. SGLT2 Inhibitors and Bladder Cancer: Analysis of Cases Reported in the European Pharmacovigilance Database.
García M; Arteche-Martinez U; Lertxundi U; Aguirre C
J Clin Pharmacol; 2021 Feb; 61(2):187-192. PubMed ID: 32827151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
